Literature DB >> 31161439

Comments on: High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany.

Amélie Cransac1, Serge Aho2, Mathieu Boulin3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31161439     DOI： 10.1007/s00520-019-04886-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  5 in total

Review 1.  Treatment for patients with newly diagnosed multiple myeloma in 2015.

Authors:  María-Victoria Mateos; Enrique M Ocio; Bruno Paiva; Laura Rosiñol; Joaquín Martínez-López; Joan Bladé; Juan-José Lahuerta; Ramón García-Sanz; Jesús F San Miguel
Journal:  Blood Rev       Date:  2015-06-12       Impact factor: 8.250

2.  A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma.

Authors:  Claire Lee; Matthew Grigorian; Ryan Nolan; Gary Binder; Gary Rice
Journal:  J Med Econ       Date:  2016-01-08       Impact factor: 2.448

3.  Medication adherence to oral anticancer drugs: systematic review.

Authors:  Wen-Chuan Huang; Chung-Yu Chen; Shun-Jin Lin; Chao-Sung Chang
Journal:  Expert Rev Anticancer Ther       Date:  2016-03-16       Impact factor: 4.512

Review 4.  Bland-Altman analysis: A paradigm to understand correlation and agreement.

Authors:  Nurettin Özgür Doğan
Journal:  Turk J Emerg Med       Date:  2018-09-17

5.  Adherence to immunomodulatory drugs in patients with multiple myeloma.

Authors:  Amélie Cransac; Serge Aho; Marie-Lorraine Chretien; Maurice Giroud; Denis Caillot; Mathieu Boulin
Journal:  PLoS One       Date:  2019-03-27       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.